New review provides practical guidance for longitudinal cardiovascular research

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Cardiovascular disease develops through gradual accumulation of risk factors and progressive vascular damage.

Longitudinal studies are well suited to determine when and how these changes occur, but they introduce several analytic challenges, including repeated measurements on the same individuals, irregular or sparse follow-up schedules, missing data, and non-linear trajectories. The authors of this article conducted a narrative, application-focused review categorizing methods into five major classes: traditional or marginal models, mixed-effect models, joint models, trajectory and mixture models, and functional or machine-learning approaches. For each class, we provide intuitive descriptions, typical cardiovascular applications, and a balanced discussion of assumptions, strengths, limitations, and recommended sensitivity analyses.

We emphasize practical guidance for method selection, model validation, and transparent reporting. In summary, no single method addresses every research goal. The analytic strategy should fit both the clinical question and data characteristics, with clear definition of objectives, careful assessment of assumptions, appropriate handling of missing data, and validation on independent samples whenever possible. Future methodological development should focus on making hybrid models more accessible, improving integration of sparse and dense data sources, and advancing reporting standards for longitudinal cardiovascular research.

Source:
Journal reference:

Chen, Y., et al. (2026) Statistical Methods for Longitudinal Cardiovascular Disease Research Design: A Narrative Review. Cardiovascular Innovations and Applications. DOI: 10.15212/CVIA.2026.0015. https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2026.0015

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)